Patents by Inventor Kurt Alex HELDWEIN

Kurt Alex HELDWEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15)
    Publication number: 20220249614
    Abstract: The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.
    Type: Application
    Filed: April 14, 2022
    Publication date: August 11, 2022
    Inventors: William CHUTKOW, John Richard Neville HADCOCK, Kurt Alex HELDWEIN, Aimee Richardson USERA
  • GFRAL EXTRACELLULAR DOMAINS AND METHODS OF USE
    Publication number: 20210340205
    Abstract: GFRAL extracellular domains comprising domains D2 and D3 are disclosed. The disclosure further relates to methods and compositions for screening and evaluating the activity of a GFRAL ligand, such as a GDF15 peptide, using the GFRAL extracellular domains provided herein. Also disclosed are methods and compositions for treating obesity, reducing appetite, and/or reducing body weight using the GFRAL extracellular domains provided herein.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 4, 2021
    Inventors: Jirong BAI, Kurt Alex HELDWEIN, Loren Daniel LINDSLEY
  • Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 10870698
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 22, 2020
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190040128
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 7, 2019
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15)
    Publication number: 20190000923
    Abstract: The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.
    Type: Application
    Filed: December 20, 2016
    Publication date: January 3, 2019
    Inventors: William CHUTKOW, John Richard Neville HADCOCK, Kurt Alex HELDWEIN, Aimee Richardson USERA
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9988455
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9982046
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 29, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170260272
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: December 23, 2016
    Publication date: September 14, 2017
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170152313
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 1, 2017
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9562101
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: February 7, 2017
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
    Publication number: 20160367638
    Abstract: A formulation comprising a modified synthetic messenger RNA and a delivery agent. The modified synthetic messenger RNA encodes a leptin protein, is non-replicating and is translation-ready. The formulation can be delivered to a subject with congenital leptin deficiency, lipodystrophy or other condition where circulating leptin level is low.
    Type: Application
    Filed: December 17, 2014
    Publication date: December 22, 2016
    Inventors: Crystal BYERS, Shari Lynn CAPLAN, Gabriel Grant GAMBER, Seung HAHM, Kurt Alex HELDWEIN, Igor SPLAWSKI, Thomas ZABAWA, Frédéric ZECRI
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9512222
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20150004168
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: January 1, 2015
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20140377281
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: December 25, 2014
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID